Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2017-11-13 Environmental & Social …
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Environmental & Social Information Classification · 99% confidence The document is a press release dated November 13, 2017, announcing that Nanobiotix presented new clinical and preclinical data regarding its NBTXR3 product at the 32nd annual meeting of the Society for Immunotherapy of Cancer (SITC). The text summarizes scientific findings (Phase II/III trial results, preclinical data) and discusses the implications for Immuno-Oncology. This format—a formal announcement detailing scientific results presented at a conference—is characteristic of an Investor Presentation (IP) or a general press release summarizing research findings, rather than a full regulatory report (like 10-K or IR) or a simple announcement of a report's publication (RPA). Since it is a detailed presentation of scientific data aimed at investors and the public, 'Investor Presentation' (IP) is the most fitting category, although it is delivered via a press release format. Given the options, 'IP' captures the essence of the content (detailed scientific/strategy update) better than 'ER' (which is for financial results) or 'RPA' (which is just an announcement of a report release).
2017-11-13 English
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 9, 2017, providing an update on the development of the lead product NBTXR3, including clinical trial statuses, upcoming conference presentations (SITC, ASCO GI), and IND application progress. This type of communication, which details operational progress, clinical milestones, and future plans without being a full financial report (like 10-K or IR) or a formal regulatory filing announcement (like RPA/RNS), most closely aligns with an Investor Presentation (IP) or a general corporate update. Since it focuses heavily on clinical pipeline progress and investor-relevant milestones, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release. It is not an Earnings Release (ER) as it does not contain period-end financial results, nor is it a formal regulatory filing announcement (RPA/RNS) because it contains substantial narrative content about the business itself, rather than just announcing the availability of another document. Given the detailed pipeline update, IP is the best fit.
2017-11-09 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Nanobiotix providing a status update on their clinical development program for NBTXR3. It details upcoming presentations at medical conferences (SITC, ASCO GI), progress on clinical trials, and regulatory status (IND submissions, CE marking). It does not contain full financial statements or audit reports, nor is it a formal regulatory filing or a report publication announcement. It functions as a corporate update on business operations and R&D progress, which falls under the category of general regulatory announcements or corporate updates, best classified as RNS. FY 2017
2017-11-09 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of October 31, 2017. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure updates. Given the options, this specific monthly disclosure about the total number of shares and voting rights aligns most closely with notifications regarding changes in significant share ownership or capital structure, which falls under Major Shareholding Notification (MRQ) or potentially a general Regulatory Filing (RNS). Since it is a specific, recurring report on the capital structure/voting rights, MRQ is a strong candidate, but the closest fit among the provided specific codes for a report detailing share count changes is often captured under general capital/shareholding updates. However, the content is a direct report of share/voting rights count, which is a key component of major shareholding disclosures or capital structure reporting. Given the explicit focus on the total number of shares and voting rights, it is a specific disclosure related to the capital base. In many contexts, this specific monthly report is classified as a Major Shareholding Notification (MRQ) or a general regulatory filing. Since it is a direct report of the capital structure count, and not an announcement *about* a report, MRQ (Major Shareholding Notification) is the most appropriate specific classification, as changes in total shares/voting rights are critical for monitoring ownership thresholds. If MRQ were not available, RNS would be the fallback. I will select MRQ as it directly relates to the underlying data monitored for major shareholdings.
2017-11-06 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 99% confidence The document is an announcement detailing the successful completion of a placement of new shares, raising approximately EUR 27.2 million via an accelerated bookbuild offering. It specifies the number of shares issued (1,941,789), the issue price (€14.00), the use of proceeds, and the resulting change in shareholding structure. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), but the substance of a capital transaction.
2017-10-31 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated October 31, 2017, announcing that NANOBIOTIX raised 27.2 million Euros through the issuance of new ordinary shares via an accelerated book-building process. Key phrases include 'placement d'actions ordinaires nouvelles' (placement of new ordinary shares), 'construction accélérée d'un livre d'ordre' (accelerated book-building), and details about the share price, capital increase, and use of proceeds. This clearly describes a financing activity involving the issuance of new capital, which aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific capital transaction.
2017-10-31 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.